For the first time, a domestically produced ultra-long-acting TSLP bispecific antibody has been approved for clinical trials.
March 9, 2026
Source: drugdu
27
On March 9, the CDE website showed that SKB575 (HBM7575) injection, jointly submitted by Kelun Biotech and Harbour BioMed , was approved for clinical trials for the treatment of atopic dermatitis .
Public information shows that SKB575 is an ultra-long-acting bispecific antibody targeting thymic stromal lymphopoietin ( TSLP) , developed in collaboration between Kelun Biotech and Harbour BioMed , and has the best potential in its class globally .
In addition, Kelun Biotech and Harbour BioMed have collaborated to develop a TSLP monoclonal antibody , SKB378 ( HBM9378) , which is currently undergoing a Phase II clinical trial for asthma. In January 2025, SKB378 was licensed to Windward Bio under a NewCo agreement with an upfront and milestone payments of $970 million.
https://mp.weixin.qq.com/s/u1rDHGr8UnkPwwZ-w3R9SQ
Copyright©2026 Ddu. All rights reserved.
Read more on
- Marketing application for HSK39297 tablets, an innovative drug for paroxysmal nocturnal hemoglobinuria, has been accepted March 9, 2026
- Clinical trial application for olopatadine-mometasone nasal spray approved by NMPA March 9, 2026
- Superior to standard therapy! Johnson & Johnson’s blockbuster new drug combination therapy receives FDA approval March 9, 2026
- With Hengrui entering the fray, can Mingrui hold its ground? March 9, 2026
- $230 million! Another BCI company completes Series C funding. March 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
